1	Low	Low	B-NP	JJ	O	2	NMOD
2	dose	dose	I-NP	NN	O	6	NMOD
3	,	,	O	,	O	6	P
4	short-term	short-term	B-NP	JJ	O	6	NMOD
5	triple	triple	I-NP	JJ	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	0	ROOT
7	for	for	B-PP	IN	O	6	NMOD
8	cure	cure	B-NP	NN	O	14	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	Helicobacter	Helicobacter	B-NP	NN	O	12	NMOD
11	pylori	pylori	I-NP	NN	O	12	NMOD
12	infection	infection	I-NP	NN	O	9	PMOD
13	and	and	I-NP	CC	O	14	NMOD
14	healing	healing	I-NP	NN	O	7	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	peptic	peptic	B-NP	JJ	O	17	NMOD
17	ulcers	ulcer	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	confirm	confirm	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	12	NMOD
10	efficacy	efficacy	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	tolerability	tolerability	I-NP	NN	O	22	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	18	NMOD
15	new	new	I-NP	JJ	O	17	AMOD
16	,	,	I-NP	,	O	17	P
17	low	low	I-NP	JJ	O	18	NMOD
18	dose	dose	I-NP	NN	O	13	PMOD
19	,	,	O	,	O	22	P
20	short-term	short-term	B-NP	JJ	O	22	NMOD
21	triple	triple	I-NP	JJ	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	8	OBJ
23	for	for	B-PP	IN	O	22	NMOD
24	cure	cure	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	Helicobacter	Helicobacter	B-NP	NN	O	28	NMOD
27	pylori	pylori	I-NP	NN	O	28	NMOD
28	infection	infection	I-NP	NN	O	25	PMOD
29	,	,	O	,	O	8	P
30	as	as	B-SBAR	IN	O	8	VMOD
31	suggested	suggest	B-VP	VBN	O	30	SBAR
32	by	by	B-PP	IN	O	31	VMOD
33	Bazzoli	Bazzoli	B-NP	NNP	O	32	PMOD
34	,	,	O	,	O	8	P
35	in	in	B-PP	IN	O	8	VMOD
36	a	a	B-NP	DT	O	38	NMOD
37	larger	large	I-NP	JJR	O	38	NMOD
38	population	population	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	6	P

1	On	On	B-PP	IN	O	39	VMOD
2	an	an	B-NP	DT	O	6	NMOD
3	``	``	I-NP	``	O	6	NMOD
4	intention-to-treat	intention-to-treat	I-NP	JJ	O	6	NMOD
5	''	''	I-NP	''	O	6	NMOD
6	basis	basis	I-NP	NN	O	1	PMOD
7	,	,	O	,	O	39	P
8	116	116	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	26	NMOD
10	with	with	B-PP	IN	O	9	NMOD
11	active	active	B-NP	JJ	O	10	PMOD
12	(	(	O	(	O	16	DEP
13	n	n	B-NP	NN	O	16	DEP
14	=	=	B-VP	SYM	O	13	NMOD
15	41	41	B-NP	CD	O	14	AMOD
16	)	)	O	)	O	11	NMOD
17	or	or	O	CC	O	26	NMOD
18	healed	heal	B-VP	VBN	O	26	NMOD
19	(	(	O	(	O	23	DEP
20	n	n	B-NP	NN	O	23	DEP
21	=	=	B-VP	SYM	O	20	NMOD
22	47	47	B-NP	CD	O	21	AMOD
23	)	)	O	)	O	18	AMOD
24	peptic	peptic	B-NP	JJ	O	26	NMOD
25	ulcer	ulcer	I-NP	NN	O	26	NMOD
26	disease	disease	I-NP	NN	O	29	NMOD
27	or	or	O	CC	O	29	NMOD
28	ulcer-like	ulcer-like	B-NP	JJ	O	29	NMOD
29	dyspepsia	dyspepsia	I-NP	NN	O	38	NMOD
30	(	(	O	(	O	34	DEP
31	n	n	B-NP	NN	O	33	SUB
32	=	=	B-VP	SYM	O	33	VMOD
33	28	28	B-NP	CD	O	34	DEP
34	)	)	O	)	O	29	NMOD
35	and	and	O	CC	O	38	NMOD
36	H.	H.	B-NP	NN	O	38	NMOD
37	pylori	pylori	I-NP	NN	O	38	NMOD
38	infection	infection	I-NP	NN	O	39	SUB
39	received	receive	B-VP	VBD	O	70	VMOD
40	a	a	B-NP	DT	O	42	NMOD
41	1-wk	1-wk	I-NP	JJ	O	42	NMOD
42	course	course	I-NP	NN	O	39	OBJ
43	of	of	B-PP	IN	O	42	NMOD
44	omeprazole	omeprazole	B-NP	NN	O	46	NMOD
45	20	20	I-NP	CD	O	46	NMOD
46	mg	mg	I-NP	NN	O	43	PMOD
47	b.i.d.	b.i.d.	B-ADVP	RB	O	39	VMOD
48	,	,	O	,	O	39	P
49	clarythromycin	clarythromycin	B-NP	NN	O	51	NMOD
50	250	250	I-NP	CD	O	51	NMOD
51	mg	mg	I-NP	NN	O	60	NMOD
52	b.i.d.	b.i.d.	B-ADVP	RB	O	51	NMOD
53	,	,	O	,	O	60	P
54	and	and	O	CC	O	60	NMOD
55	tinidazole	tinidazole	B-NP	NN	B-protein	57	NMOD
56	500	500	I-NP	CD	I-protein	57	NMOD
57	mg	mg	I-NP	NN	I-protein	60	NMOD
58	b.i.d..	b.i.d..	B-NP	RB	I-protein	60	NMOD
59	Four	Four	I-NP	CD	I-protein	60	NMOD
60	weeks	week	I-NP	NNS	I-protein	61	PMOD
61	after	after	B-PP	IN	O	70	VMOD
62	treatment	treatment	B-NP	NN	O	63	NMOD
63	withdrawal	withdrawal	I-NP	NN	O	61	PMOD
64	,	,	O	,	O	70	P
65	cure	cure	B-NP	NN	O	70	SUB
66	of	of	B-PP	IN	O	65	NMOD
67	H.	H.	B-NP	NN	O	69	NMOD
68	pylori	pylori	I-NP	NN	O	69	NMOD
69	infection	infection	I-NP	NN	O	66	PMOD
70	was	be	B-VP	VBD	O	0	ROOT
71	evaluated	evaluate	I-VP	VBN	O	70	VC
72	by	by	B-PP	IN	O	71	VMOD
73	rapid	rapid	B-NP	JJ	O	75	NMOD
74	urease	urease	I-NP	NN	O	75	NMOD
75	test	test	I-NP	NN	O	77	NMOD
76	and	and	I-NP	CC	O	77	NMOD
77	histology	histology	I-NP	NN	O	72	PMOD
78	.	.	O	.	O	70	P

1	One	One	B-NP	CD	O	5	NMOD
2	hundred	hundred	I-NP	CD	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	sixteen	sixteen	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	returned	return	B-VP	VBD	O	0	ROOT
7	for	for	B-PP	IN	O	6	VMOD
8	follow-up	follow-up	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	7	VMOD
2	108	108	B-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	H.	H.	B-NP	NN	O	6	NMOD
6	pylori	pylori	I-NP	NN	O	7	SUB
7	could	could	B-VP	MD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	be	be	I-VP	VB	O	7	VC
10	identified	identify	I-VP	VBN	O	9	VC
11	4	4	B-NP	CD	O	12	NMOD
12	wk	wk	I-NP	NN	O	10	OBJ
13	after	after	B-PP	IN	O	12	NMOD
14	cessation	cessation	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	therapy	therapy	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	3	NMOD
2	eradication	eradication	I-NP	NN	O	3	NMOD
3	rate	rate	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	calculated	calculate	I-VP	VBN	O	4	VC
6	to	to	B-PP	TO	O	5	VMOD
7	93	93	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	10	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	10	P
4	all	all	B-NP	DT	O	5	NMOD
5	patients	patient	I-NP	NNS	O	10	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	active	active	B-NP	JJ	O	9	NMOD
8	peptic	peptic	I-NP	JJ	O	9	NMOD
9	ulcers	ulcer	I-NP	NNS	O	6	PMOD
10	showed	show	B-VP	VBD	O	0	ROOT
11	complete	complete	B-NP	JJ	O	12	NMOD
12	healing	healing	I-NP	NN	O	10	OBJ
13	at	at	B-PP	IN	O	12	NMOD
14	follow-up	follow-up	B-NP	NN	O	13	PMOD
15	despite	despite	B-PP	IN	O	10	VMOD
16	no	no	B-NP	DT	O	18	NMOD
17	further	further	I-NP	JJ	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	10	P

1	Drug	Drug	B-NP	NN	O	2	NMOD
2	acceptance	acceptance	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	compliance	compliance	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	excellent	excellent	B-ADJP	JJ	O	5	PRD
7	.	.	O	.	O	5	P

1	Triple	Triple	B-NP	JJ	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	42	SUB
3	as	as	B-SBAR	IN	O	2	NMOD
4	suggested	suggest	B-VP	VBN	O	3	SBAR
5	by	by	B-PP	IN	O	4	VMOD
6	Bazzoli	Bazzoli	B-NP	NNP	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	omeprazole	omeprazole	B-NP	NN	O	24	VMOD
9	(	(	O	(	O	18	DEP
10	in	in	B-PP	IN	O	18	DEP
11	this	this	B-NP	DT	O	12	NMOD
12	study	study	I-NP	NN	O	10	PMOD
13	given	give	B-VP	VBN	O	12	NMOD
14	b.i.d.	b.i.d.	B-ADVP	RB	O	13	VMOD
15	for	for	B-PP	IN	O	13	VMOD
16	better	good	B-NP	JJR	O	17	NMOD
17	compliance	compliance	I-NP	NN	O	15	PMOD
18	)	)	O	)	O	8	NMOD
19	,	,	O	,	O	24	P
20	clarythromycin	clarythromycin	B-NP	NN	O	24	VMOD
21	,	,	O	,	O	24	P
22	and	and	O	CC	O	24	VMOD
23	tinidazole	tinidazole	B-NP	NN	O	24	SUB
24	is	be	B-VP	VBZ	O	7	SBAR
25	indeed	indeed	B-ADVP	RB	O	24	VMOD
26	highly	highly	B-ADJP	RB	O	25	AMOD
27	effective	effective	I-ADJP	JJ	O	24	PRD
28	for	for	B-PP	IN	O	27	AMOD
29	both	both	O	CC	O	30	NMOD
30	cure	cure	B-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	H.	H.	B-NP	NN	O	34	NMOD
33	pylori	pylori	I-NP	NN	O	34	NMOD
34	infection	infection	I-NP	NN	O	31	PMOD
35	and	and	B-PP	CC	O	28	PMOD
36	for	for	B-PP	IN	O	28	PMOD
37	healing	healing	B-NP	NN	O	36	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	peptic	peptic	B-NP	JJ	O	40	NMOD
40	ulcers	ulcer	I-NP	NNS	O	38	PMOD
41	,	,	O	,	O	2	P
42	is	be	B-VP	VBZ	O	0	ROOT
43	easy	easy	B-ADJP	JJ	O	42	PRD
44	to	to	B-VP	TO	O	45	VMOD
45	perform	perform	I-VP	VB	O	43	AMOD
46	,	,	O	,	O	42	P
47	is	be	B-VP	VBZ	O	42	VMOD
48	cheap	cheap	B-ADJP	JJ	O	47	PRD
49	,	,	O	,	O	42	P
50	and	and	O	CC	O	42	VMOD
51	is	be	B-VP	VBZ	O	42	VMOD
52	without	without	B-PP	IN	O	51	PRD
53	clinically	clinically	B-NP	RB	O	54	AMOD
54	significant	significant	I-NP	JJ	O	56	NMOD
55	side	side	I-NP	NN	O	56	NMOD
56	effects	effect	I-NP	NNS	O	52	PMOD
57	,	,	O	,	O	51	P
58	even	even	B-ADVP	RB	O	59	PMOD
59	in	in	B-PP	IN	O	51	VMOD
60	a	a	B-NP	DT	O	62	NMOD
61	larger	large	I-NP	JJR	O	62	NMOD
62	population	population	I-NP	NN	O	59	PMOD
63	.	.	O	.	O	42	P

